Corporate Update: Teva Pharmaceutical Industries Limited
Market Snapshot
On Friday, 23 October 2026, Teva Pharmaceutical Industries Limited (ticker TEVA.TA) closed the trading day at ILS 124.1, reflecting a 2.1 % decline from the previous close. The stock is currently listed on the Tel Aviv Stock Exchange with a circulating supply of 1.2 billion shares. Its market capitalisation stands at ILS 40.2 billion, and the firm saw ILS 26.6 billion of its shares exchanged in the last 24 hours. Despite the recent dip, the stock has posted a 4.49 % gain since the end of the previous month.
The 200‑day simple moving average sits at ILS 10 412.68, providing a long‑term context for the current price. Historically, Teva’s 52‑week high was ILS 13 070 on 20 October 2026, while the 52‑week low was ILS 6 207 on 26 October 2025.
Comparative Performance
In the same 24‑hour window, several peer companies exhibited varied trajectories:
| Company | Ticker | 24‑hr Movement | Current Price | Market Capitalisation | P/E Ratio |
|---|---|---|---|---|---|
| Phoenix | PHOE.TA | +1.73 % | ILS 185.4 | ILS 13.1 bn | 14.46 |
| Camtek | CAMT | –10.23 % | USD 119.48 | USD 6.1 bn | 217.69 |
| Enlight Renewable Energy | ENLT | –3.49 % | USD 69.32 | USD 8.5 bn | 114.46 |
| Check Point Software | CHKP | +5.96 % | USD 151.98 | USD 14.6 bn | 14.69 |
| Nova | NVMI | –6.37 % | USD 310.13 | USD 8.9 bn | 41.49 |
These figures illustrate a mixed market environment: while Teva and Phoenix experienced modest gains, Camtek and Nova faced significant declines. Notably, Check Point Software demonstrated robust growth, underscoring the sector’s resilience.
Company Overview
Teva Pharmaceutical Industries Limited is a leading global player in the pharmaceutical arena, specialising in the development, manufacturing, and marketing of both generic and branded human pharmaceuticals, as well as active pharmaceutical ingredients. The firm’s extensive portfolio serves customers worldwide, positioning it as a key contributor to global health and medication accessibility. Further details on Teva’s operations and corporate strategy can be found on its official website at www.tevapharm.com .
Outlook
Analysts will likely monitor Teva’s quarterly earnings reports, particularly any updates on its generic portfolio and potential new drug approvals, to gauge whether the current price dip represents a buying opportunity or a temporary market correction. The firm’s sizeable market capitalisation and steady trading volume suggest that it remains an attractive prospect for investors seeking exposure to the pharmaceutical sector.
